PremiumThe FlyAnika Therapeutics reports Q1 adjusted EPS (6c) vs. 13c last year Anika Therapeutics sees FY25 adjusted EBITDA down 3% to up 3% Is ANIK a Buy, Before Earnings? PremiumCompany AnnouncementsAnika Therapeutics’ Earnings Call: Growth Amid Challenges Anika Therapeutics price target lowered to $20 from $25 at Barrington Anika Therapeutics Reports Steady Growth and Strategic Focus PremiumThe FlyAnika Therapeutics price target lowered to $25 from $37 at Barrington Anika Therapeutics Focuses on Core Growth Amid Restructuring Anika Therapeutics Refocuses on Core Technology and Growth